No Data
No Data
Vicore Expands and Strengthens Its Board of Directors
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2024 Earnings Conference
The following is a summary of the MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript:Financial Performance:MaxCyte reported a total revenue of $11.3 million in Q1 2024, a rise of 32% from the $8.6
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2024 Earnings Call Transcript
MaxCyte Shares Rise Sharply After Q1 Results Beat
MaxCyte (MXCT) shares were up more than 20% in recent Wednesday trading after the company reported better-than-expected Q1 results in the previous day. The company reported late Tuesday a Q1 loss of $
Express News | MaxCyte Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results